{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-179404","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.968166+00:00","generated_at":"2026-05-15T03:54:20.167133+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer","bullets":["ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.","Grade 3 hyperglycemia 0% despite 47% pre-diabetic; only 3% discontinued zovegalisib due to TRAEs.","Phase 3 trial of zovegalisib + atirmociclib + AI in 1L PIK3CA-mutated HR+/HER2- breast cancer expected to start early 2027.","Pfizer to supply atirmociclib and palbociclib for the trial; Relay retains full rights to zovegalisib.","Median follow-up 7.4 months; 77% of patients remain on study; median PFS not yet mature."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-179404","json":"https://secwatch.observer/filing/0001193125-26-179404.json","markdown":"https://secwatch.observer/filing/0001193125-26-179404.md","text":"https://secwatch.observer/filing/0001193125-26-179404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526179404/0001193125-26-179404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526179404/rlay-20260427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:54:20.167133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}